MedNet Solutions Launches the iMedNet CRO Partner Program
MedNet Solutions
announced the official launch of its
iMedNet
CRO Partner Program. Designed specifically to help Clinical Research Organizations (CROs) improve research efficiency, expand their service offerings, decrease internal costs, and win more business, the program provides CROs with marketplace advantages.
At the core of the program is
iMedNet EDC
, MedNet's recently released cloud-based, software-as-a-service (SaaS) eClinical solution that allows non-technical clinical research personnel to quickly and easily set up and maintain their own EDC studies.
iMedNet EDC's
intuitive study configuration tools and form libraries allow studies to be set up in days, not weeks or months. Even entire studies can be replicated in a matter of seconds.
Key additional program features include:
- Affordable Pricing – iMedNet's CRO Partner pricing model eliminates upfront fees and dramatically lowers overall costs making iMedNet EDC practical for all research initiatives–even pre-clinical and Phase I studies.
- Comprehensive iMedNet Designer Training – MedNet provides a complete iMedNet EDC training and certification program ensuring that all CRO personnel involved in the design and configuration of iMedNet studies are versed in the capabilities of the system.
- Full Sales and Marketing Support – MedNet directly supports the sales efforts of iMedNet CRO Partners with a complete range of services, from marketing materials and demonstration support, to prospective customer referrals and joint promotional activities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
